CONNECT BIOPHARMA HOLD

Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis

01 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update

11 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California

06 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Connect Biopharma Provides Business and Clinical Development Program Update

30 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Connect Biopharma to Present at the San Francisco Biotech Showcase in January

19 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

02 Dec 2022 16:00:00 By Nasdaq GlobeNewswire

Connect Biopharma To Present at Upcoming Investor and Scientific Conferences

27 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

04 Oct 2022 07:56:48 By Nasdaq GlobeNewswire

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

04 Oct 2022 06:00:01 By Nasdaq GlobeNewswire

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

03 Oct 2022 15:10:00 By Nasdaq GlobeNewswire

Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update

13 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Connect Biopharma to Report First Half 2022 Financial Results on September 13

01 Sep 2022 07:00:02 By Nasdaq GlobeNewswire

Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study

30 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

11 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

17 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Connect Biopharma to Participate at the Jefferies Healthcare Conference

02 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference

17 May 2022 15:05:00 By Nasdaq GlobeNewswire

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

03 May 2022 15:05:01 By Nasdaq GlobeNewswire

Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update

31 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer

01 Mar 2022 07:00:15 By Nasdaq GlobeNewswire